149 related articles for article (PubMed ID: 10416685)
1. Expression of von Hippel-Lindau protein in normal and pathological human tissues.
Sakashita N; Takeya M; Kishida T; Stackhouse TM; Zbar B; Takahashi K
Histochem J; 1999 Feb; 31(2):133-44. PubMed ID: 10416685
[TBL] [Abstract][Full Text] [Related]
2. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
3. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
Siemeister G; Weindel K; Mohrs K; Barleon B; Martiny-Baron G; Marmé D
Cancer Res; 1996 May; 56(10):2299-301. PubMed ID: 8625303
[TBL] [Abstract][Full Text] [Related]
4. Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues.
Corless CL; Kibel AS; Iliopoulos O; Kaelin WG
Hum Pathol; 1997 Apr; 28(4):459-64. PubMed ID: 9104946
[TBL] [Abstract][Full Text] [Related]
5. Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis.
Richards FM; Schofield PN; Fleming S; Maher ER
Hum Mol Genet; 1996 May; 5(5):639-44. PubMed ID: 8733131
[TBL] [Abstract][Full Text] [Related]
6. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
Jensen RL; Gillespie D; House P; Layfield L; Shelton C
J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
[TBL] [Abstract][Full Text] [Related]
7. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
[TBL] [Abstract][Full Text] [Related]
8. Expression pattern of the von Hippel-Lindau protein in human tissues.
Los M; Jansen GH; Kaelin WG; Lips CJ; Blijham GH; Voest EE
Lab Invest; 1996 Aug; 75(2):231-8. PubMed ID: 8765323
[TBL] [Abstract][Full Text] [Related]
9. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma.
Ananth S; Knebelmann B; Grüning W; Dhanabal M; Walz G; Stillman IE; Sukhatme VP
Cancer Res; 1999 May; 59(9):2210-6. PubMed ID: 10232610
[TBL] [Abstract][Full Text] [Related]
12. Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma.
Perera AD; Kleymenova EV; Walker CL
Clin Cancer Res; 2000 Apr; 6(4):1518-23. PubMed ID: 10778984
[TBL] [Abstract][Full Text] [Related]
13. Expression of the Von Hippel-Lindau tumor suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis.
Kessler PM; Vasavada SP; Rackley RR; Stackhouse T; Duh FM; Latif F; Lerman MI; Zbar B; Williams BR
Mol Med; 1995 May; 1(4):457-66. PubMed ID: 8521303
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of ocular angiogenesis by an adenovirus carrying the human von Hippel-Lindau tumor-suppressor gene in vivo.
Akiyama H; Tanaka T; Itakura H; Kanai H; Maeno T; Doi H; Yamazaki M; Takahashi K; Kimura Y; Kishi S; Kurabayashi M
Invest Ophthalmol Vis Sci; 2004 May; 45(5):1289-96. PubMed ID: 15111579
[TBL] [Abstract][Full Text] [Related]
16. Tumour suppression by the human von Hippel-Lindau gene product.
Iliopoulos O; Kibel A; Gray S; Kaelin WG
Nat Med; 1995 Aug; 1(8):822-6. PubMed ID: 7585187
[TBL] [Abstract][Full Text] [Related]
17. Endoplasmic reticulum/cytosolic localization of von Hippel-Lindau gene products is mediated by a 64-amino acid region.
Schoenfeld AR; Davidowitz EJ; Burk RD
Int J Cancer; 2001 Feb; 91(4):457-67. PubMed ID: 11251966
[TBL] [Abstract][Full Text] [Related]
18. [Von Hippel-Lindau disease].
Shuin T; Ashida S; Yao M; Kanno H
Nihon Rinsho; 2000 Jul; 58(7):1448-54. PubMed ID: 10921322
[TBL] [Abstract][Full Text] [Related]
19. Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system.
Gläsker S; Bender BU; Apel TW; van Velthoven V; Mulligan LM; Zentner J; Neumann HP
J Neurol Neurosurg Psychiatry; 2001 May; 70(5):644-8. PubMed ID: 11309459
[TBL] [Abstract][Full Text] [Related]
20. An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association.
Cohen HT; Zhou M; Welsh AM; Zarghamee S; Scholz H; Mukhopadhyay D; Kishida T; Zbar B; Knebelmann B; Sukhatme VP
Biochem Biophys Res Commun; 1999 Dec; 266(1):43-50. PubMed ID: 10581162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
